PharmaCyte Biotech, Inc. - 23 May 2024 Form 3 Insider Report for MyMD Pharmaceuticals, Inc. (TNFA)

Role
10%+ Owner
Signature
/s/ Carlos Trujillo, Chief Financial Officer
Issuer symbol
TNFA
Transactions as of
23 May 2024
Net transactions value
$0
Form type
3
Filing time
30 May 2024, 16:05:04 UTC
Previous filing
28 Nov 2023
Next filing
18 Nov 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding MYMD Series G Convertible Preferred Stock 23 May 2024 Common stock, par value $0.001 per share 3,854,626 $1.82 Direct F1
holding MYMD Warrants 23 May 2024 Common stock, par value $0.001 per share 3,854,626 $1.82 Direct
holding MYMD Warrants 23 May 2024 Common stock, par value $0.001 per share 3,854,626 $1.82 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Series G Convertible Preferred Stock is convertible at any time, at the holder's election, and has no expiration date.